Patient responds well to Patrys's PAT-SM6

Patrys (ASX:PAB) has announced that a patient with relapsed multiple myeloma responded positively to its anticancer candidate PAT-SM6 when administered as a combination therapy.

The patient was granted permission to receive PAT-SM6 on an “individual treatment” basis under the supervision of Professor Einsele, at the University of Würzburg Hospital in Germany, who led Patrys’s recent phase I/IIa multiple myeloma trial.

The patient is a 61-year-old male who was diagnosed with multiple myeloma in 2013. After four cycles of combination chemotherapy and an autologous stem cell transplant (SCT), the patient initially went into complete remission. But six months after the procedure, he relapsed.

After another four cycles of combination chemotherapy, the patient suffered another relapse, with several tumours appearing both inside and outside the bone marrow, including in the testes.

Based on preclinical data suggesting that PAT-SM6 as part of a combination therapy can kill multiple myeloma cells that are otherwise resistant to drug therapy, Einsele decided to treat the relapsed patient with a combination of PAT-SM6, Velcade and Revlimid.

After three doses of this combination therapy, a PET-CT scan revealed significant shrinkage of both the extramedullary (outside of the bone marrow) and the intramedullary (inside of bone marrow) lesions. The tumour in the testes even disappeared.

“This patient, who has very difficult to treat myeloma, had an excellent response to PAT-SM6 when it was used with other myeloma drugs,” Patrys CEO Dr Marie Roskrow said.

“The fact that he received a proteosome inhibitor (Velcade) as part of the treatment protocol with PAT-SM6 is particularly important as Patrys’s next clinical trial will be using a second-generation proteosome inhibitor (Carfilzomib) in combination with PAT-SM6.”

Patrys (ASX:PAB) shares were trading unchanged at $0.035 as of around 12.30 pm on Thursday.